Lead Strategist — Small caps, momentum plays, and options strategies.
Ross Givens is a veteran trader with over 15 years of experience navigating the markets. A former VP at a major Wall Street investment bank, Ross left the institutional world to pursue his passion: helping everyday traders access the same caliber of market intelligence that was once reserved for the privileged few.
Specializing in small-cap stocks and momentum-driven plays, Ross has built a reputation for identifying high-probability setups before they hit the mainstream radar. His approach combines deep fundamental research with technical precision, focusing on insider activity, institutional accumulation patterns, and breakout formations that signal explosive moves.
As Lead Strategist at Traders Agency, Ross has guided hundreds of successful trades and developed multiple flagship publications that have become essential tools for our community. His work has been featured on CNBC, Fox Business, and Bloomberg, and he holds active FINRA licenses that underscore his commitment to professional standards.
Preferred Markets
Small Caps & Options
Timeframe
Swing (2-10 days)
Strategy
Momentum & Breakouts
Track Record
See results
Actionable trading intelligence delivered through multiple formats to match your style.
$599 Your mission-ready squad for live trades, breakout setups, and insider market intel.
$297 Detect when Wall Street whales are accumulating positions before the crowd.
$297 Live trading sessions with real-time analysis and trade ideas every week.
$4,995 Ross's flagship stock picks service targeting excess returns over the market.
$4,995 “Home run” stock setups in ANY MARKET using the #1 best performing trading strategy of all time.
$4,997 Follow company insiders -- CEOs, directors, executives -- to big stock gains.
$4,997 Detect unusual options activity and position ahead of market-moving information.
Nvidia investments shift toward humanoid robots as one pure-play stock emerges. See why smart money is targeting physical AI now.
Money flows have been violently rotating over the past 12 months – all in one confusing mess. How can any trader spot the opportunity within?
See why this FDA just approved stock list pick, Stereotaxis (STXS), trades at $1.65 with analysts eyeing 150% upside after key approvals.
50,000+ traders get our daily brief before the market opens.
You're subscribed!
Check your inbox.
Free. No spam. Unsubscribe anytime.